Biomerieux SA
PAR:BIM

Watchlist Manager
Biomerieux SA Logo
Biomerieux SA
PAR:BIM
Watchlist
Price: 121 EUR 0.58%
Market Cap: 14.3B EUR

Net Margin
Biomerieux SA

10.9%
Current
13%
Average
1.7%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
10.9%
=
Net Income
432.2m
/
Revenue
4B

Net Margin Across Competitors

Biomerieux SA
Glance View

Economic Moat
None
Market Cap
14.3B EUR
Industry
Health Care

In the world of clinical diagnostics, bioMérieux SA emerges as a formidable player, weaving together a tapestry of innovation, precision, and reliability. Founded in 1963 by Alain Mérieux, the company has its roots deeply embedded in Lyon, France, where a legacy of scientific prowess meets a global vision. bioMérieux specializes in in vitro diagnostics, creating a broad array of products and solutions that essentially serve as the medical community’s early warning systems. Their expertise spans across fields like microbiology, immunoassays, and molecular biology, where they craft diagnostic kits and automated instruments that empower healthcare providers to detect and prevent diseases with remarkable accuracy. By tapping into a robust network of research and development, bioMérieux collaborates with hospitals, laboratories, and public health organizations worldwide to address both routine and critical diagnostic needs. At the heart of bioMérieux’s business is its razor-sharp focus on infectious diseases, a sector that has seen accelerated growth in recent years, particularly with the advent of global health challenges such as the COVID-19 pandemic. The firm generates revenue through the sale of its diagnostic solutions and related services, offering comprehensive testing systems that include reagents and consumables, maintenance contracts, and training for laboratory professionals. Their continuous investment in innovation allows them to expand their product portfolio and tailor solutions to the evolving needs of the healthcare industry. By maintaining a pulse on global health trends and investing in cutting-edge technologies, bioMérieux not only secures its market position but also plays a crucial role in strengthening global public health infrastructure.

BIM Intrinsic Value
HIDDEN
Show
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
10.9%
=
Net Income
432.2m
/
Revenue
4B
What is the Net Margin of Biomerieux SA?

Based on Biomerieux SA's most recent financial statements, the company has Net Margin of 10.9%.

Back to Top